Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2a Single Dose and 28-day Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream 0.5% and 0.15% in Adults With Mild to Moderate Chronic Plaque Psoriasis

Next Previous
Trial Profile

A Phase 1/2a Single Dose and 28-day Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream 0.5% and 0.15% in Adults With Mild to Moderate Chronic Plaque Psoriasis

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Roflumilast (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Sponsors Arcutis Biotherapeutics

Most Recent Events

  • 24 Nov 2022 Results assessing the pharmacokinetic profile of roflumilast delivered topically from a phase I maximal usage study and data from phase II and phase III studies (NCT04279119, NCT03392168, NCT04211363, NCT04211389), published in the American Journal of Clinical Dermatology.
  • 03 Aug 2020 Primary endpoint (4 Week TPSS x TPA) has been met, according to an an Arcutis Biotherapeutics Media Release.
  • 03 Aug 2020 Accoording to an Arcutis Biotherapeutics Media Release, results from this trial were published in an article in the August 2020 issue of The Journal of Drugs in Dermatology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top